Changes in the epidemiology of invasive fungal infections and impact of primary prophylaxis with voriconazole in a pediatric cohort of bone marrow trasplants recipients
Vol. 21 No. 2 (2017), Original articles
Vol. 21 No. 2 (2017)

Changes in the epidemiology of invasive fungal infections and impact of primary prophylaxis with voriconazole in a pediatric cohort of bone marrow trasplants recipients

Original articles
Published 2019-04-27
A Juliá
Hospital de Pediatría “Prof. Dr. Juan P. Garrahan”
CM Figueroa Turienzo
Hospital de Pediatría “Prof. Dr. Juan P. Garrahan”
M Roizen
Hospital de Pediatría “Prof. Dr. Juan P. Garrahan”
C Epelbaum
Hospital de Pediatría “Prof. Dr. Juan P. Garrahan”
P Santos
Hospital de Pediatría “Prof. Dr. Juan P. Garrahan”
R Staciuk
Hospital de Pediatría “Prof. Dr. Juan P. Garrahan”
ISSN 2250-8309 (versión en línea) - ISSN 0329-0379 (versión impresa)
pdf (Español (España))

Keywords

Invasive fungal infections, HSCT, Antifungal primary prophylaxis

How to Cite

Juliá, A., Figueroa Turienzo, C., Roizen, M., Epelbaum, C., Santos, P., & Staciuk, R. (2019). Changes in the epidemiology of invasive fungal infections and impact of primary prophylaxis with voriconazole in a pediatric cohort of bone marrow trasplants recipients. Journal of Hematology, 21(2), 143–148. Retrieved from https://mail.revistahematologia.com.ar/index.php/Revista/article/view/146
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Invasive fungal infections (IFI) are an important cause of morbidity and mortality after hematopoietic stem cell transplantation (HSCT). At the end of 2013, due to an increase in IFI by FF, our hospital decided to change antifungal primary prophylaxis with fluconazole for voriconazole during neutropenia up to 100 days after HSCT. Objective: to analyse effects of the change of antifungal primary prophylaxis in a retrospective cohort of recipients of HSCT. Materials and methods: we performed a retrospective analysis of all patients, who underwent HSCT at Hospital Garrahan between 2012-2013 (P1) and 2014- 2015 (P2); we analyzed patients that showed IFI. Results: frequency of IFI, transplant related mortality (TRM), and direct mortality due to IFI (DMIFI) in recipients of HSCT with antifungal primary prophylaxis. IFI: P1, 21/55 (38,1%) vs. P2 6/47 (12,7%) p 0,047. IFI due to yeasts: P1 9/55 (16,3%) vs. P2 3/47 (6,3%). IFI due to FF: P1 12/55 (21,8%) vs. P2 3/47 (6,3%) p 0,047. TRM: P1 21/55 (38,1%) vs. P2 7/47 (14,8%) p <0,01. DMIFI: P1 5/55 (9%) vs. P2 0/47 (0%) Conclusion: primary prophylaxis with voriconazole was associated with a decrease in IFI due to HF FF and DMIFI. There was also a decrease in TRM between both periods. The risk of mucormycosis emergency requires strict epidemiological follow-up.

pdf (Español (España))

References

1. Dimitrios P. Kontoyiannis, Kieren A. Marr, Benjamin J. Park et al. Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, 2001–2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clinical Infectious Diseases. 2010; 50:1091–1100.
2. Lourdes Vázquez, Miguel Salavert, Jorge Gayoso et al. Delphi-based study and analysis of key risk factors for invasive fungal infection in haematological patients. Rev Esp Quimioter.
2017;30(2): 103-117.
3. Carol Garcia-Vidal, Arlo Upton, Katharine A. Kirby et al. Epidemiology of Invasive Mold Infections in Allogeneic Stem Cell Transplant Recipients: Biological Risk Factors for Infection
According to Time after Transplantation. Clin Infect Dis. 2008 ; 47(8): 1041–1050.
4. MCEthier,MScience,JBeyene et al.Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials. British Journal of Cancer. 2012; 106: 1626–1637.
5. Trifilio S, Singhal S, Williams S et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow
Transplantation. (2007) 40, 451–456.
6. Forés R, Ramos A, Orden B et al. Rhodotorula species fungaemia causes low mortality in haematopoietic stem-cell transplantation. A case report and review. Mycoses. 2012; 55(3):e158-62.
7. Bartelink IH1, Wolfs T, Jonker M et al. Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients. Antimicrob Agents Chemother.
2013 ; 57(1):235-40.
8. HaiyingJin, Tiansheng Wang, Bonnie A. Falcione et al. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis. J Antimicrob Chemother. 2016; 71: 1772 –1785.
9. Amigues I, Cohen N, Chung D et al. Hepatic Safety of Voriconazole after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010; 16(1): 46–52.
10. Patel AR, Turner ML, Baird K et al. Voriconazole-induced phototoxicity masquerading as chronic graft-versus-host disease of the skin in allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2009 Mar;15(3):370-6.
11. Epaulard O, Leccia MT, Blanche S et al. Phototoxicity and photocarcinogenesis associated with voriconazole. Med Mal Infect. 2011; 41(12):639-45.
12. Solano C, Slavin M, Shaul AJ et al. Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant. Mycoses. 2016; 1–10.
13. Ying Jiao Zhao, Ai LengKhoo, Gloria Tan et al. Network Meta-analysis and Pharmacoeconomic Evaluation of Fluconazole, Itraconazole, Posaconazole, and Voriconazole in Invasive Fungal Infection Prophylaxis. Antimicrob Agents Chemother. 2015; 60(1):376-86.

All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar

Downloads

Download data is not yet available.